The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management.
The medication is now cleared by the FDA for clinical use in perioperative settings, marking a key development in the medical application of ketamine, according to an Aug. 11 news release from the drugmaker.
PharmaTher said it intends to develop more ketamine-based therapies for conditions including depression, Parkinson’s disease, ALS and chronic pain disorders such as complex regional pain syndrome.
The decision comes amid ongoing concerns about ketamine shortages in the U.S. and follows a 2023 alert from the FDA warning about risks of compounded ketamine formulations used for psychiatric treatment.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
